非甾体抗炎药治疗膝髋骨关节炎疼痛的有效性:一项网络Meta分析
该网络Meta分析纳入76项随机试验共58451例患者,比较非甾体抗炎药、对乙酰氨基酚或安慰剂对膝髋骨关节炎疼痛的疗效。结果显示双氯芬酸150 mg/日与依托考昔60 mg/日达到最小临床重要差异的概率最高,均为100%;单药对乙酰氨基酚无论剂量均无角色。
要点
- 所有非甾体抗炎药制剂无论剂量均较安慰剂改善疼痛点估计值。
- 双氯芬酸150 mg/日与依托考昔60 mg/日达到最小临床重要差异的概率均为100%。
- 单药对乙酰氨基酚无论剂量均无角色。
核心结论
- 基于现有数据,单药对乙酰氨基酚无论剂量均无角色用于骨关节炎患者治疗;双氯芬酸150 mg/日是目前在改善疼痛和功能方面最有效的非甾体抗炎药。
- 鉴于这些药物的安全性特征,医生为个体患者选择制剂和剂量时需将本结果与所有已知安全性信息一并考虑。
研究设计与样本
- 网络Meta分析,检索Cochrane对照试验中心注册库(CENTRAL)及参考文献,时间范围为1980年1月1日至2015年2月24日,纳入每组至少100例患者的随机试验。
- 共纳入76项随机试验,总计58451例患者;涉及7种不同非甾体抗炎药或对乙酰氨基酚按特定日剂量给药的23个节点及安慰剂。
- 采用多变量贝叶斯随机效应模型扩展进行混合多重治疗比较,试验水平设随机效应;主要分析用一阶随机游走处理试验内多次随访数据。
主要发现
- 所有制剂无论剂量均较安慰剂改善疼痛症状的点估计值。
- 六种干预(双氯芬酸150 mg/日、依托考昔30 mg/日、60 mg/日、90 mg/日、罗非昔布25 mg/日、50 mg/日)与安慰剂差异达到预设最小临床重要效应(效应量[ES] -0.37)或以下的概率至少95%。
- 在最大批准日剂量中,双氯芬酸150 mg/日(ES -0.57,95%可信区间[CrI] -0.69至-0.45)与依托考昔60 mg/日(ES -0.58,-0.74至-0.43)成为最佳干预的概率最高,两者达到最小临床重要差异的概率均为100%。
- 治疗效应随药物剂量增加而增加,但线性剂量效应检验仅萘普生显著(p=0.034)。
- 未发现治疗效应随治疗持续时间变化的证据;模型拟合良好,试验间异质性和不一致性在所有分析中均低。
关键数值与推荐
- 预设最小临床重要效应为疼痛减轻效应量[ES] -0.37。
- 双氯芬酸150 mg/日:ES -0.57,95%CrI -0.69至-0.45。
- 依托考昔60 mg/日:ES -0.58,95%CrI -0.74至-0.43。
- 线性剂量效应检验仅萘普生显著(p=0.034)。
临床怎么用
- 作者认为单药对乙酰氨基酚无论剂量均无角色用于骨关节炎患者治疗。
- 作者指出双氯芬酸150 mg/日是目前在改善疼痛和功能方面最有效的非甾体抗炎药。
- 作者建议医生为个体患者选择制剂和剂量时需将本结果与所有已知安全性信息一并考虑。
局限性
- 所有试验被判定为患者盲法低偏倚风险。
- 效应估计在两种额外统计模型及Meta回归分析中考虑方法学质量标准后未改变。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are the backbone of osteoarthritis pain management. We aimed to assess the effectiveness of different preparations and doses of NSAIDs on osteoarthritis pain in a network meta-analysis. METHODS: For this network meta-analysis, we considered randomised trials comparing any of the following interventions: NSAIDs, paracetamol, or placebo, for the treatment of osteoarthritis pain. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the reference lists of relevant articles for trials published between Jan 1, 1980, and Feb 24, 2015, with at least 100 patients per group. The prespecified primary and secondary outcomes were pain and physical function, and were extracted in duplicate for up to seven timepoints after the start of treatment. We used an extension of multivariable Bayesian random effects models for mixed multiple treatment comparisons with a random effect at the level of trials. For the primary analysis, a random walk of first order was used to account for multiple follow-up outcome data within a trial. Preparations that used different total daily dose were considered separately in the analysis. To assess a potential dose-response relation, we used preparation-specific covariates assuming linearity on log relative dose. FINDINGS: We identified 8973 manuscripts from our search, of which 76 randomised trials with a total of 58 451 patients were included in this analysis. 23 nodes concerning seven different NSAIDs or paracetamol with specific daily dose of administration or placebo were considered. All preparations, irrespective of dose, improved point estimates of pain symptoms when compared with placebo. For six interventions (diclofenac 150 mg/day, etoricoxib 30 mg/day, 60 mg/day, and 90 mg/day, and rofecoxib 25 mg/day and 50 mg/day), the probability that the difference to placebo is at or below a prespecified minimum clinically important effect for pain reduction (effect size [ES] -0·37) was at least 95%. Among maximally approved daily doses, diclofenac 150 mg/day (ES -0·57, 95% credibility interval [CrI] -0·69 to -0·45) and etoricoxib 60 mg/day (ES -0·58, -0·74 to -0·43) had the highest probability to be the best intervention, both with 100% probability to reach the minimum clinically important difference. Treatment effects increased as drug dose increased, but corresponding tests for a linear dose effect were significant only for naproxen (p=0·034). We found no evidence that treatment effects varied over the duration of treatment. Model fit was good, and between-trial heterogeneity and inconsistency were low in all analyses. All trials were deemed to have a low risk of bias for blinding of patients. Effect estimates did not change in sensitivity analyses with two additional statistical models and accounting for methodological quality criteria in meta-regression analysis. INTERPRETATION: On the basis of the available data, we see no role for single-agent paracetamol for the treatment of patients with osteoarthritis irrespective of dose. We provide sound evidence that diclofenac 150 mg/day is the most effective NSAID available at present, in terms of improving both pain and function. Nevertheless, in view of the safety profile of these drugs, physicians need to consider our results together with all known safety information when selecting the preparation and dose for individual patients. FUNDING: Swiss National Science Foundation (grant number 405340-104762) and Arco Foundation, Switzerland.
引用
- da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017. PMID: 28699595. doi:10.1016/S0140-6736(17)31744-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。